From GlobeNewswire: 2025-03-27 07:30:00

Bicara Therapeutics Inc. has begun dosing patients in the FORTIFI-HN01 trial, a Phase 2/3 study of ficerafusp alfa for recurrent/metastatic head and neck cancer. Updated data will be presented at the 2025 ASCO Annual Meeting. The company has a strong financial position with $490 million in cash to fund operations until the first half of 2029.

The pivotal Phase 2/3 trial, FORTIFI-HN01, is currently enrolling patients for ficerafusp alfa in combination with pembrolizumab for 1L recurrent/metastatic head and neck squamous cell carcinoma. Updated data from an ongoing Phase 1/1b trial will be presented at the 2025 ASCO Annual Meeting.

Bicara Therapeutics is developing ficerafusp alfa, a dual-action antibody targeting EGFR and TGF-β for various solid tumor types. The company aims to expand the use of ficerafusp alfa to other head and neck cancer populations and solid tumor types.

Financially, Bicara reported a cash position of $490 million as of December 31, 2024, with research and development expenses totaling $19.9 million for the fourth quarter. The company’s net loss for the year ended December 31, 2024, was $67.9 million.

Bicara Therapeutics is dedicated to bringing innovative bifunctional therapies to patients with solid tumors. Ficerafusp alfa, their lead program, aims to target EGFR and TGF-β for potent anti-tumor activity. The company is actively involved in clinical trials and conference presentations to advance their research.



Read more at GlobeNewswire:: Bicara Therapeutics Reports Fourth Quarter and Full Year